Papers
6
Total Citations
444
H-Index
4
About
Andrew Feber is a leading urological surgeon and researcher whose work centers on improving surgical outcomes for patients with bladder and prostate cancer. His major contributions lie in the rigorous evaluation of robot-assisted surgical techniques, most notably through the landmark iROC trial. This multi-centre randomised controlled trial compared robot-assisted radical cystectomy with intracorporeal urinary diversion to open radical cystectomy, with his 2022 paper on the subject accumulating over 320 citations and reshaping clinical practice. Feber’s research demonstrates that total intracorporeal robotic surgery can reduce morbidity and enhance recovery without compromising oncologic safety. Beyond bladder cancer, he has pioneered innovative tissue collection pathways for prostate cancer research, using MRI data to target tumor and benign tissue in fresh specimens—work that supports the development of improved diagnostics and treatments. His investigations also extend to the use of wearable devices and cardiopulmonary exercise testing to predict major complications after radical cystectomy, reflecting a commitment to personalised preoperative assessment. With a portfolio of highly cited work that directly influences surgical standards, Feber is a pivotal figure in advancing minimally invasive urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6